Roles of the immune system in cancer: from tumor initiation to metastatic progression

By Hugo Gonzalez, C. Hagerling, Zena Werb. Genes & Development, 2018

1,769 citations recorded by the source corpus.

In this review, Gonzelez et al. provide an update of recent accomplishments, unifying concepts, and futures challenges to study tumor-associated immune cells, with an emphasis on metastatic carcinomas.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d40ce3670efdc3c6509aae01f089afe50ce4a107

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Dey
2. Arvind K. Singh Chandel
3. Rupa Sanyal
4. Amarnath Mishra
5. D. Pandey
6. V. De Falco
7. Arun Prakash Upadhyay
8. J. M. Pérez de la Lastra

Citations in the corpus

• Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “197 Recent research has focused on tumor immunotherapy as a promising approach to tackle this challenge.”
• Dynamic EMT: a multi‐tool for tumor progression (2021, neutral): “In a simplified model, macrophage-tumor crosstalk generates a variety of tumor-associated macrophage (TAM) phenotypes, with an M1-like state promoting elimination of immunogenic tumor cells and a contrasting pro-tumorigenic M2-like state (Gonzalez et al , 2018).”
• Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “At early stages, most known biomarkers remain undetectable, and cancer cells’ ability to hide from immune cells freezes our immune responses.(82,83) In a tumor subpopulation, transformed cells differ drastically from the other cells in terms of physiology, metabolism, proliferation rate, etc.”